 "Dishman Pharma hits new high; stock surges over 35% in two days")
Dishman Pharmaceuticals and Chemicals hit a fresh record high of Rs 322, up 16% on BSE on back of heavy volumes after the company on Tuesday said that its partner Tesaro Inc received US Food and Drug Administration (FDA) nod for cancer drug Zejula capsules.
The stock of drug maker has rallied 39% in past two trading sessions from Rs 232 on March 27, 2017.
“We believe that the increase in the stock price is based upon market estimation that we are one of the suppliers of the API for "Zejula" capsules, which got approved by the US FDA as per the press release given by Tesaro lnc,” Dishman Pharma said in a regulatory filing.
Since the company does not manufacture the innovator's end product in CRAMS segment, it is Tesaro lnc., which has received the US FDA approval for cancer drug Zejula Capsules, it added.
At 09:30 am; the stock was up 12% at Rs 310 as compared to 0.15% rise in the S&P BSE Sensex. The trading volumes on the counter surged more than five-fold with a combined 6.86 million shares changed hands on the BSE and NSE so far.
The stock of drug maker has rallied 39% in past two trading sessions from Rs 232 on March 27, 2017.
“We believe that the increase in the stock price is based upon market estimation that we are one of the suppliers of the API for "Zejula" capsules, which got approved by the US FDA as per the press release given by Tesaro lnc,” Dishman Pharma said in a regulatory filing.
Since the company does not manufacture the innovator's end product in CRAMS segment, it is Tesaro lnc., which has received the US FDA approval for cancer drug Zejula Capsules, it added.
At 09:30 am; the stock was up 12% at Rs 310 as compared to 0.15% rise in the S&P BSE Sensex. The trading volumes on the counter surged more than five-fold with a combined 6.86 million shares changed hands on the BSE and NSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%